BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 19686542)

  • 1. Anti-CD20 antibody rituximab in the treatment of rheumatoid arthritis.
    Korhonen R; Moilanen E
    Basic Clin Pharmacol Toxicol; 2010 Jan; 106(1):13-21. PubMed ID: 19686542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Targeting CD20 in rheumatoid arthritis].
    Saito K; Tanaka Y
    Nihon Rinsho; 2007 Jul; 65(7):1243-9. PubMed ID: 17642239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [B cell depletion therapy using anti-CD20 antibodies in rheumatoid arthritis].
    Yukawa N; Mimori T
    Clin Calcium; 2007 Apr; 17(4):569-76. PubMed ID: 17404487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus.
    Goldblatt F; Isenberg DA
    Handb Exp Pharmacol; 2008; (181):163-81. PubMed ID: 18071946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
    Teng YK; Levarht EW; Hashemi M; Bajema IM; Toes RE; Huizinga TW; van Laar JM
    Arthritis Rheum; 2007 Dec; 56(12):3909-18. PubMed ID: 18050222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long term treatment of rheumatoid arthritis with rituximab.
    Caporali R; Caprioli M; Bobbio-Pallavicini F; Bugatti S; Montecucco C
    Autoimmun Rev; 2009 Jun; 8(7):591-4. PubMed ID: 19393205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab for rheumatoid arthritis.
    Palylyk-Colwell E; McGahan L
    Issues Emerg Health Technol; 2006 Sep; (89):1-4. PubMed ID: 17014062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current aspects of anti-CD20 therapy in rheumatoid arthritis.
    Jacobi AM; Dörner T
    Curr Opin Pharmacol; 2010 Jun; 10(3):316-21. PubMed ID: 20189875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy.
    Bokarewa M; Lindholm C; Zendjanchi K; Nadali M; Tarkowski A
    Scand J Immunol; 2007 Oct; 66(4):476-83. PubMed ID: 17850593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocrelizumab: a step forward in the evolution of B-cell therapy.
    Kausar F; Mustafa K; Sweis G; Sawaqed R; Alawneh K; Salloum R; Badaracco M; Niewold TB; Sweiss NJ
    Expert Opin Biol Ther; 2009 Jul; 9(7):889-95. PubMed ID: 19463076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of rheumatoid arthritis with rituximab: an update and possible indications.
    De Vita S; Quartuccio L
    Autoimmun Rev; 2006 Aug; 5(7):443-8. PubMed ID: 16920570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Rituximab (Mabthera)--treatment of rheumatoid arthritis patients with inadequate response to TNF inhibitors--when to change therapy?].
    Morović-Vergles J
    Reumatizam; 2008; 55(2):70-2. PubMed ID: 19024280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging biologic drugs for the treatment of rheumatoid arthritis.
    Puppo F; Murdaca G; Ghio M; Indiveri F
    Autoimmun Rev; 2005 Nov; 4(8):537-41. PubMed ID: 16214092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Rituximab (MabThera)--a new biological medicine in rheumatoid arthritis therapy].
    Nemec P
    Vnitr Lek; 2007 Nov; 53(11):1199-210. PubMed ID: 18277630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects of rituximab in rheumatoid arthritis: clinical, biologic, and pharmacogenetic aspects.
    Quartuccio L; Lombardi S; Fabris M; Masolini P; Saracco M; Pellerito R; De Vita S
    Ann N Y Acad Sci; 2009 Sep; 1173():692-700. PubMed ID: 19758217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is the role of rituximab in the treatment of rheumatoid arthritis?
    Atzeni F; Doria A; Turiel M; Sarzi-Puttini P
    Autoimmun Rev; 2007 Sep; 6(8):553-8. PubMed ID: 17854748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Panel discussion on B cells and rituximab: mechanistic aspects, efficacy and safety in rheumatoid arthritis and non-Hodgkin's lymphoma.
    Panayi GS; Hainsworth JD; Looney RJ; Keystone EC
    Rheumatology (Oxford); 2005 May; 44 Suppl 2():ii18-ii20. PubMed ID: 15851523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab treatment of refractory rheumatoid arthritis.
    Summers KM; Kockler DR
    Ann Pharmacother; 2005 Dec; 39(12):2091-5. PubMed ID: 16249269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab therapy in patients with resistant rheumatoid arthritis: real-life experience.
    Jois RN; Masding A; Somerville M; Gaffney K; Scott DG
    Rheumatology (Oxford); 2007 Jun; 46(6):980-2. PubMed ID: 17384180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application.
    Mease PJ
    J Rheumatol; 2008 Jul; 35(7):1245-55. PubMed ID: 18609733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.